Welichem Filed Quarterly Report for Period Ended November 30, 2007



    BURNABY, BC, Jan. 25 /CNW/ - Welichem Biotech Inc. (the "Company")
(TSX-V: WBI), announced today that the Company filed its second quarter
financials and MD&A. The net loss for the three month period ended November
30, 2007 was $493,483 (2006 - $831,878) or 1 cent per share (2006 - 2 cents
per share). The net loss for the six month period ended November 30, 2007 was
$1,086,587 (2006 - $1,698,579) or 2 cent per share (2006 - 3 cents per share).
    Detailed information is available on SEDAR website (www.sedar.com).

    About Welichem Biotech Inc.

    Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and cancer.

    ON BEHALF OF THE BOARD

    York Yingping Guo
    President & Chief Executive Officer

    The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements.

    %SEDAR: 00021386E




For further information:

For further information: York Yingping Guo, Tel.: (604) 432-1703, Email:
yorkguo@welichem.com

Organization Profile

Welichem Biotech Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890